Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 12, Issue 5, Pages 553-556Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2008.03.007
Keywords
accutrend (R) meter; hyperlactatemia; lactic acidosis; point-of-care (POC) devices; highly active antiretroviral therapy (HAART)
Categories
Ask authors/readers for more resources
Background: The use of highly active antiretroviral therapy (HAART) results in multiple side effects that may jeopardize the life of the patient being treated with antiretroviral drugs. In resource-poor settings it is difficult to definitively diagnose lactic acidosis by laboratory measurement of lactate. Point-of-care (POC) devices are helpful in the measurement of lactate levels and have been validated in the intensive care unit setting, but not in a busy outpatient clinic. The objective of this study was to assess the sensitivity and specificity of the Accutrend (R) lactate meter in the diagnosis of hyperlactatemia/lactic acidosis in patients on nucleoside reverse transcriptase inhibitor (NRTI)-containing regimens (stavudine). Design and methods: This was a cross-sectional study of 120 patients on HAART (lamivudine, stavudine, efavirenz, or nevirapine) with symptoms of/or recovering from hyperlactatemia/lactic acidosis. Simultaneous testing of the same blood sample was undertaken on the Accutrend (R) handheld lactate analyzer and a reference instrument (Beckman CX7 Synchron (R) machine). A venous lactate level <2.2 mmol/l was considered as normal. Results: The mean lactate value obtained from the Accutrend (R) meter was 2.89 mmol/l and from the reference instrument was 2.78 mmol/l. The standard deviation for Accutrend (R) meter was 1.14 mmol/l vs. 1.42 mmol/l. for the Beckman instrument. The sensitivity obtained for the Accutrend (R) meter was 95.9% (95% CI 87.7-98.9%) and the specificity 63.8% (95% CI 48.5- 76.9%). The positive predictive value was 80.5% (95% CI 70.3-87.9%) and the negative predictive value was 90.9% (95% CI 74.5 -97.6%). Conclusions: The Accutrend (R) lactate meter is an appropriate device for screening patients on HAART with symptoms of hyperlactatemia/lactic acidosis. The use of this device decreases analytic and intervention time, preventing further morbidity and mortality in patients on an NRTI (stavudine)-based regimen. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available